Key opinion leaders discuss how bispecifics are administered at their institutions.
Multiple Myeloma Experts Face Off on Sequencing Therapy Options
Experts in multiple myeloma gathered to debate current treatment options in the space during a recent Face Off.
Mitigating AEs and Protecting QOL Following Talquetamab in Multiple Myeloma
Samantha Shenoy, NP, MSN, discusses how her role plays a vital part in patient care for those receiving talquetamab for multiple myeloma.
Using Real-World Data to Form GPRC5D Therapy Strategies in R/R Multiple Myeloma
Experts in multiple myeloma discussed real-world efficacy and safety data associated with the use of GPRC5D-targeting bispecific agents to treat patients with R/R multiple myeloma.
Exploring the Potential Role of JAK Inhibitors in Multiple Myeloma
James R. Berenson, MD, describes ongoing efforts to evaluate treatment with JAK inhibitors like ruxolitinib among patients with multiple myeloma.
Anito-Cel Shows Promising Results in Relapsed/Refractory Multiple Myeloma
Early results from the iMMagine-1 trial show anito-cel as a promising therapy in relapsed/refractory multiple myeloma.
FDA, EMA Receive Applications for Subcutaneous Daratumumab in Myeloma
Data from the phase 3 AQUILA study support the applications for subcutaneous daratumumab in high-risk smoldering multiple myeloma.
